Enanta Pharmaceuticals (NASDAQ:ENTA) Given Buy Rating at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Wednesday, MarketBeat.com reports. They currently have a $20.00 target price on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 58.23% from the company’s current price.

A number of other analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA traded up $0.03 during mid-day trading on Wednesday, reaching $12.64. The company had a trading volume of 322,819 shares, compared to its average volume of 205,564. The stock has a fifty day moving average of $13.14 and a two-hundred day moving average of $13.30. The company has a market capitalization of $368.08 million, a price-to-earnings ratio of -5.24 and a beta of 0.93. Enanta Pharmaceuticals has a 12-month low of $9.91 and a 12-month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The company had revenue of $14.36 million during the quarter, compared to analysts’ expectations of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. Sell-side analysts forecast that Enanta Pharmaceuticals will post -2.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ENTA. Hillsdale Investment Management Inc. acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth $6,660,000. Spruce Street Capital LP acquired a new stake in Enanta Pharmaceuticals during the second quarter worth $15,873,698. Janus Henderson Group PLC boosted its stake in Enanta Pharmaceuticals by 1.5% during the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after buying an additional 54,396 shares in the last quarter. Jupiter Topco LLC acquired a new stake in Enanta Pharmaceuticals during the second quarter worth $53,252,000. Finally, BlackRock Inc. acquired a new stake in Enanta Pharmaceuticals during the second quarter worth $47,304,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company’s research has primarily centered on antiviral medicines, including treatments for respiratory syncytial virus (RSV), hepatitis B, and other infectious diseases.

Enanta is best known for its role in the development of glecaprevir, a protease inhibitor used with pibrentasvir in AbbVie’s Mavyret (also marketed as Maviret) treatment for chronic hepatitis C virus infection.